aspirin / Generic mfg. - LARVOL DELTA

Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial. (PubMed, Eur Heart J) - "The quality of VKA management as measured by TTR correlates with the occurrence of non-surgical bleeding in patients with the HM3 LVAD, with a lower TTR associated with an increased bleeding risk. These data provide new clinical direction to define a benchmark TTR to achieve further mitigation of residual risk of bleeding and enhance haemocompatibility with the HM3 LVAD."

Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Thrombosis

Myopericarditis and Pulmonary Edema. (PubMed, J Educ Teach Emerg Med) - "The most commonly missed intervention was administering aspirin or ibuprofen, and none considered advanced circulatory support despite persistent hypotension. Points learned while implementing the case were that, 1) its degree of difficulty is more suitable for senior rather than junior learners because it involves a critically ill patient with multiple simultaneous issues to be managed, 2) it requires a well-rounded and systematic approach to achieve all critical actions, and 3) the appropriate prompts should be utilized to cover all aspects in the allotted 15 minutes for the case. Myopericarditis, pulmonary edema, cardiogenic shock, sepsis, septic shock."

Journal • Cardiovascular • Hypotension • Infectious Disease • Inflammation • Pain • Rare Diseases • Respiratory Diseases • Septic Shock

Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. (PubMed, N Engl J Med) - P4 | "Among patients who had had successful catheter ablation for atrial fibrillation at least 1 year earlier and had risk factors for stroke, treatment with rivaroxaban did not result in a significantly lower incidence of a composite of stroke, systemic embolism, or new covert embolic stroke than treatment with aspirin. (Funded by Bayer and others; OCEAN ClinicalTrials.gov number, NCT02168829.)."

Journal • Atrial Fibrillation • Cardiovascular • Ischemic stroke

Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease? (PubMed, Eur Heart J) - "Special attention is given to the practical challenges and considerations surrounding the use of aspirin vs P2Y12 inhibitor monotherapy, including interindividual variability in drug response, side effects, costs, and real-world implementation. By evaluating the strengths and limitations of these treatment options, this article aims to guide clinicians in optimizing the selection of single antiplatelet strategies for long-term secondary prevention in patients with atherosclerotic disease."

Journal • Monotherapy • Atherosclerosis • Cardiovascular

Role of Previous Sinus Surgery Extent in Indication of Biologic Treatment for CRSwNP. (PubMed, J Craniofac Surg) - "Fifty-four patients (76%) met biologic eligibility criteria (mean age 54 years; 46% female; 76% asthma; 19% aspirin-exacerbated respiratory disease)...After revision ESS, 45 patients (83%) achieved disease control, whereas 9 (17%) remained uncontrolled (8 required dupilumab, 1 underwent extended surgery)...Extent of prior ESS, quantified by ACCESS, is associated with postoperative outcomes in CRSwNP patients eligible for biologics. Low ACCESS scores predict need for biologics, supporting ACCESS as a tool for treatment selection in the biologic era."

Journal • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

The History of Coronary Artery Disease. (PubMed, Int J Angiol) - "The progression of medical therapies, including the discovery and utilization of digitalis, nitrates, aspirin, beta blockers, and statins, is discussed alongside the evolution of catheter-based and surgical interventions such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)...Despite remarkable progress, CAD remains a major public health challenge, emphasizing the importance of continued innovation in prevention, diagnosis, and treatment. Understanding the historical trajectory of CAD provides critical insights for shaping the future of cardiovascular medicine."

Journal • Review • Atherosclerosis • Cardiovascular • Coronary Artery Disease

Delayed Stanford type A aortic dissection after transcatheter aortic valve implantation with balloon-expandable valve: a case report. (PubMed, J Surg Case Rep) - "In this case, postoperative down-titration of antihypertensive agents and dual antithrombotic therapy (aspirin and edoxaban) may have contributed to the progression of the intramural hematoma and dissection. Although delayed AAD has been predominantly reported in association with self-expanding valves, this case highlights that multiple factors can contribute to AAD with balloon-expandable valves. Therefore, patients with AAD risk factors should be closely monitored."

Journal • Cardiovascular

Genetic Evidence Linking Lipoprotein(a) to Cardiovascular Disease and the Potential Role of Aspirin: A Mendelian Randomization Study. (PubMed, Rev Cardiovasc Med) - "A causal nexus was discerned between Lp(a) levels and an increased risk of conditions including coronary artery disease, atrial fibrillation, heart failure, hypertension, and peripheral artery disease. Furthermore, administering aspirin may be a potential therapeutic to reduce these CVD risks among individuals with elevated Lp(a) levels."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertension • Peripheral Arterial Disease

Early Aspirin Withdrawal after Percutaneous Coronary Intervention in Acute Coronary Syndromes With and Without ST-Segment Elevation: Results from the NEO-MINDSET trial (AHA 2025) - "We evaluated early aspirin withdrawal effects on ischemic and bleeding outcomes according to ACS presentation.Study Design and Pre-specified analysis of the NEO-MINDSET trial according to ACS presentation (STEMI and NSTE-ACS)Sample Size: 3,410 patients: STEMI (n=1,058 monotherapy, n=1,061 DAPT); NSTE-ACS (n=654 monotherapy, n=637 DAPT).Population Studied: ACS patients undergoing successful PCI with drug-eluting stents within 4 days of admission.Intervention: Potent P2Y12 inhibitor monotherapy (prasugrel or ticagrelor) with immediate aspirin discontinuation versus standard DAPT with a potent P2Y12 inhibitor for 12 months.Power Calculations: Not performed for this prespecified analysis.Primary Endpoints: Co-primary endpoints were: 1) the composite of all-cause death, myocardial infarction, stroke, or urgent target-vessel revascularization; and 2) Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding.Secondary Endpoints: Individual components of the..."

Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

The Need for Ongoing Oral Anticoagulation in Patients with Clinical Stroke Risk Factors After Successful Catheter Ablation of Atrial Fibrillation: The OCEAN Randomized Trial (AHA 2025) - P4 | "Patients were randomized to either antiplatelet therapy (acetylsalicylic acid 75-120 mg daily) or oral anticoagulation (rivaroxaban 15 mg daily). Anticipated database lock is August 15, 2025, 36 months after enrollment of the last patient. Results of the primary efficacy endpoint and safety endpoint (bleeding) will be presented.CONCLUSIONOCEAN will be the first randomized trial to evaluate whether ongoing OAC is necessary after successful AF ablation in patients with stroke risk factors."

Clinical • Late-breaking abstract • Atrial Fibrillation • Cardiovascular • Ischemic stroke

Weekly Journal Scan: the NEO-MINDSET of early aspirin discontinuation in patients with acute coronary syndromes is neither justified nor safe. (PubMed, Eur Heart J) - No abstract available

Journal • Acute Coronary Syndrome • Cardiovascular

Kawasaki disease shock syndrome with extreme leukemoid reaction mimicking hematologic malignancy in an IVIG-resistant child: A case report. (PubMed, Medicine (Baltimore)) - "This case emphasizes that KDSS with leukemoid reaction may mimic hematologic malignancy, delaying appropriate immunomodulatory therapy. Extreme leukocytosis (≥70 × 109/L) should not exclude KDSS, especially in children with unexplained fever and shock. Early recognition, adjunctive corticosteroid therapy, and individualized anticoagulation strategies are critical to prevent misdiagnosis and improve outcomes."

Journal • Cardiovascular • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypotension • Leukemia • Oncology • Pediatrics • Vasculitis • CRP

Aspirin for Primary Prevention of Cardiovascular Disease: A Contemporary Review. (PubMed, Cardiol Rev) - "This article provides us with an overall summary of the evidence for aspirin primary prevention of CVD, taking into account prominent trials, the balance between benefits (eg, reduction in myocardial infarction) and harms (eg, bleeding), evolving clinical guidelines, and practical considerations of risk stratification and patient selection. Our work tried to highlight the manner in which aspirin's use in primary prevention in current practice is narrowly focused and should be individualized by careful consideration of risk-benefit and shared decision-making."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Myocardial Infarction

Portal hypertension caused by essential thrombocythemia: A case report. (PubMed, Medicine (Baltimore)) - "ET can also lead to PHT, portal vein thrombosis, and esophageal varices. Clinicians should consider these possibilities when dealing with such patients."

Journal • Cardiovascular • Essential Thrombocythemia • Fibrosis • Gastroenterology • Hematological Disorders • Hypertension • Immunology • Myeloproliferative Neoplasm • Oncology • Oral Cancer • Portal Hypertension • Thrombocytosis • Thrombosis • JAK2

Metabolomic and network Pharmacology insights into the anti-inflammatory and anti-urolithiatic potential of Ficus religiosa seeds. (PubMed, Sci Rep) - "In vitro assays demonstrated that the ethyl acetate extract significantly inhibited red blood cell hemolysis (IC50: 346.63 ± 1.303 µg/ml) and protein denaturation (IC50: 524.10 ± 1.29 µg/ml), highlighting strong anti-inflammatory effects comparable to diclofenac and acetylsalicylic acid...Molecular docking further validated the high binding affinities of flavonoids and phytosterols with central regulatory proteins such as PI3K, AKT1, IKKβ, MMP-9, and CaMKII, supporting their roles in inflammatory suppression and extracellular matrix remodeling. Overall, this study validates the ethnomedicinal use of Ficus religiosa seeds for the treatment of urinary and inflammatory disorders and highlights their bioactive, multitarget therapeutic potential for managing urolithiasis, warranting further preclinical and clinical evaluation."

Journal • Hematological Disorders • Inflammation • Renal Calculi • Urolithiasis • AKT1 • MMP9

Risk factors, stroke rates and aspirin prescribing trends in the Canadian Fabry disease initiative cohort. (PubMed, Orphanet J Rare Dis) - "There was a high incidence of stroke/TIA in the younger CFDI cohort compared to the general Canadian population, despite low levels of traditional vascular risk factors as represented in 10-year estimated ASCVD risk. Primary prevention use of ASA has declined."

Journal • Atherosclerosis • Cardiovascular • Fabry Disease • Genetic Disorders • Ischemic stroke

Reversion of multidrug resistance in clinical isolates of Escherichia coli using non-steroidal anti-inflammatory drugs (NSAIDs). (PubMed, J Antibiot (Tokyo)) - "Clinical E. coli strains were exposed to antibiotics (ciprofloxacin, tetracycline, ampicillin) with or without NSAIDs (acetylsalicylic acid, ibuprofen). NSAIDs potentiate antibiotic activity against resistant E. coli, likely through membrane disruption. This adjuvant approach could help combat AMR and warrants further investigation."

Journal • Infectious Disease

Sense of Smell Improvements with Tezepelumab in Patients with Chronic Rhinosinusitis with Nasal Polyps (WAYPOINT) (ACAAI 2025) - P3 | "Smell outcomes were assessed in the following subgroups: sex, region, time since CRSwNP diagnosis, previous NP surgery, NP score at baseline, comorbid asthma, comorbid aspirin-exacerbated respiratory disease (AERD) and comorbid allergic rhinitis (AR). Compared with placebo, tezepelumab-treated patients demonstrated improvements in smell outcomes across baseline CRSwNP disease characteristic subgroups (time since CRSwNP diagnosis, history of NP surgery and NP score) and comorbidity subgroups (comorbid asthma or AERD status at baseline, and comorbid AR at screening) ( Figure ). Conclusions Improvements in smell outcomes were observed in patients with uncontrolled CRSwNP across multiple subgroups with tezepelumab compared with placebo in the WAYPOINT study."

Clinical • Allergic Rhinitis • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Atypical Adverse Reaction with Unclear Mechanism after Celecoxib Exposure (ACAAI 2025) - "He was treated with oral cetirizine and symptoms began resolving within 40 minutes. After a risk benefit discussion, the patient passed an oral aspirin challenge, demonstrating tolerance to COX-1 inhibition allowing for utilization of alternative NSAIDs for use in upcoming surgeries...The second reaction had a delayed onset within 3-4 hours with milder symptoms. His clinical presentation would be atypical for an IgE mediated reaction, making it unclear whether an alternative mechanism was involved."

Dermatology • Immunology • Urticaria

Biologic Therapy in CRSwNP: Sustained Outcomes and Real-World Evidence. (ACAAI 2025) - "Results Patients demonstrated a high prevalence of T2 comorbidities, including allergic rhinitis and aspirin-exacerbated respiratory disease...71% of patients had prior exposure to other biologics (omalizumab)...Conclusion The collective findings of this study support the use of eosinophil-targeted biologic therapy, as an effective strategy for achieving sustained clinical improvement in patients with CRSwNP. No significant differences were observed between mepolizumab and benralizumab, both demonstrating positive impact on symptoms, olfactory function, and radiologic and endoscopic findings."

Clinical • HEOR • Real-world • Real-world evidence • Allergic Rhinitis • Asthma • Chronic Obstructive Pulmonary Disease • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Mucositis • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Clinical Characteristics Associated with Post-Operative Nasal Polyp Recurrence in Chronic Rhinosinusitis with Nasal Polyps (ACAAI 2025) - "Patients with fast-recurrence AERD had higher IgE than slow-recurrence AERD (p<0.01); but fast vs. slow aspirin-tolerant CRSwNP participants had no difference in serum IgE. Conclusions Patients with fast-recurrence have higher rates of comorbid asthma, highlighting the shared pathophysiology of upper and lower airway disease, elevated BEC and serum IgE, which can be useful tools for closer monitoring or early adjuvant therapy. With no significant difference in allergic rhinitis or atopic dermatitis, this suggests that while atopy is prevalent in CRSwNP, its utility as a response to treatment is limited."

Clinical • Allergic Rhinitis • Asthma • Atopic Dermatitis • Chronic Rhinosinusitis With Nasal Polyps • Dermatitis • Dermatology • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Aspirin For More Than Just A Hangover (ACAAI 2025) - "Before the widespread use of biologics, aspirin desensitization emerged as a safe and effective therapeutic option for aspirin intolerance and subsequent studies have shown efficacy in alcohol-associated AERD symptoms. Outpatient aspirin desensitization is a cost-effective, beneficial therapy that can restore quality of life for patients with AERD, particularly those experiencing alcohol-induced exacerbations."

Allergic Rhinitis • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pruritus • Respiratory Diseases • Sinusitis

A Case for Aspirin Desensitization (ACAAI 2025) - No abstract available

Clinical • Chronic Rhinosinusitis With Nasal Polyps • Sinusitis

Multifaceted Approach to Patients with AERD and CRSwNP (ACAAI 2025) - "Description The approach for aspirin exacerbated respiratory disease has changed over the past decade; however, many patients may benefit from a more targeted approach...Objective 2: Discern when topical steroids and leukotriene modifying agents should be used and discuss the various forms of application of these products. Objective 3: Describe situations when biologics should be considered and advantages/disadvantages against other therapies."

Clinical • Chronic Rhinosinusitis With Nasal Polyps • Respiratory Diseases

Modulatory Effects of Lannea welwitschia on Cadmium-Induced Reproductive and Biochemical Dysregulation via Steroidogenic Enzyme Regulation in Female Rats. (PubMed, J Ethnopharmacol) - "Lannea welwitschii bark extract protects against CdCl2-induced female reproductive toxicity by modulating oxidative stress, restoring hormonal balance, and regulating steroidogenesis-related genes, thereby supporting its traditional use and potential therapeutic value for female infertility associated with environmental toxins."

Journal • Preclinical • Gynecology • Hematological Disorders • Infertility • Sexual Disorders • IL6 • TNFA